Cancer/tumor profiling assists in individualizing cancer
treatment by providing useful information at the molecular or genetic level.
This helps medical practitioners to design an appropriate treatment for
patients suffering from cancer. This technique assists in studying an
individuals cancer cells and in analyzing the genetic characteristics and
unique biomarkers. The information obtained post cancer profiling is used to
identify and create targeted therapies that are designed to work better for a
specific cancer tumor profile.
Download Sample
Report: https://www.alliedmarketresearch.com/request-sample/2717
The advent of tumor/cancer profiling has assisted in
overcoming the limitation of traditional cancer diagnostic methods as well as
setting up a gold standard for tumor classification. The targeted approach
especially using NGS technology delivers high sensitivity to detect tumor
subclone and rare mutations by detecting the mutation-causing agent in cancer.
This has ultimately fueled the adoption of cancer profiling methods among
oncologists. In addition, rapid rise in burden of cancer and increase in funding
from government for devising cancer diagnosing methods augment the market
growth. However, high monetary investments for the development of biomarkers
and dearth of skilled oncologists & related professionals restrain the
market growth. Moreover, untapped markets, such as China and India, offer
lucrative opportunities for the market growth due to rise in demand for better
diagnosis and treatment of various types of cancer.
The fluorescence in situ hybridization (FISH) segment
generated the highest revenue in 2016, and is anticipated to dominate the
market throughout the forecast period. This attributed to increase in demand
for FISH in cancer profiling, as this technology helps in identifying the
predictive or prognostically important genetic variants in cancer, and is
successfully used for the prediction prognosis of breast cancer.
The metabolomics segment is expected to witness the highest
growth rate in the global market registering a CAGR of 20.2% from 2017 to 2023,
owing to the recent advances in metabolomics technologies that have deeper
insights about the metabolism of cancer. Moreover, determining the abundance of
all the metabolites in a cancer cells is possible through metabolomics
profiling techniques.
The personalized medicine segment accounted for one-fourth
share of the global market in 2016, and is expected to register the highest
CAGR of 19.1% throughout the forecast period. This is attributed to increased
focus of oncologists towards personalized cancer care, thereby ensuring better
treatment methods with fewer side effects. Furthermore, personalized medicines
offer better understanding of genetic differences in patients to govern the
susceptibility to a particular cancer or response to a specific treatment. This
aids in providing targeted therapy, thereby decreasing the overall cost of
treatment with minimal side effects to patients.
Get Detail Report https://www.alliedmarketresearch.com/cancer-tumor-profiling-market
0 Comments